The non-hormonal therapies market is growing at an annualized rate of 21.7%, claims Roots Analysis

Driven by the potential to confer safe and sustained therapeutic effects for clinical conditions unique to women, the non-hormonal therapies pipeline is growing, featuring candidates having improved risk profiles and lesser side effects

Roots Analysis has announced the addition of “Non-hormonal Therapies for Women’s Health Market 2021 – 2030” report to its list of offerings.

In pursuit of an advantageous and risk-free prospect to hormonal therapies, the success of 21 approved non-hormonal therapies has resulted in a surge in the interest of drug developers in this rapidly evolving domain. As a result, the non-hormonal therapies market is abuzz with activity, in terms of partnerships and funding initiatives.

To order this 225+ page report, which features 92+ figures and 154+ tables, please visit https://www.rootsanalysis.com/reports/non-hormonal-therapies-for-women-health-market.html

Key Market Insights

Around 55 non-hormonal therapies are currently being developed across different stages
Apart from 21 approved products, close to 58% of the aforementioned candidates are being evaluated in clinical stages of development, with 2% of therapies in preclinical stages. It is worth mentioning that more than 80% of such drugs are small molecules. Further, majority of the therapies are being developed for the treatment of endometriosis (19%).

Over 64% of the non-hormonal therapy developers are based in North America
Interestingly, within the aforementioned region, majority of the players (21) are based in the US, which is considered a prominent R&D hub for advanced therapeutic products. Moreover, the current market is dominated by the presence of small players and very large firms, respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *